Advanced

High Survivin Levels Predict Poor Clinical Response to Infliximab Treatment in Patients with Rheumatoid Arthritis

Isgren, Anniella; Forslind, Kristina LU ; Erlandsson, Malin; Axelsson, Carl; Andersson, Sofia; Lund, Anneli and Bokarewa, Maria (2012) In Seminars in Arthritis and Rheumatism 41(5). p.652-657
Abstract
Objective: To evaluate if the measurement of survivin in the blood of patients with rheumatoid arthritis (RA) undergoing infliximab treatment has predictive value for treatment response. Methods: The study included 87 consecutive RA patients (age 24-89 years, disease duration 18-526 months) treated with regular infusions of influximab. Survivin levels were measured by enzyme-linked immunosorbent assay and evaluated in relation to the total dose of infliximab, disease activity (DAS28), response to infliximab treatment (change in DAS28 > 1.2), and radiographic damage (vdH-Sharp score). Results: Thirty-seven percent of patients were survivin-positive (survivin > 0.9 ng/mL) and showed severe radiographic damage at the start of infliximab... (More)
Objective: To evaluate if the measurement of survivin in the blood of patients with rheumatoid arthritis (RA) undergoing infliximab treatment has predictive value for treatment response. Methods: The study included 87 consecutive RA patients (age 24-89 years, disease duration 18-526 months) treated with regular infusions of influximab. Survivin levels were measured by enzyme-linked immunosorbent assay and evaluated in relation to the total dose of infliximab, disease activity (DAS28), response to infliximab treatment (change in DAS28 > 1.2), and radiographic damage (vdH-Sharp score). Results: Thirty-seven percent of patients were survivin-positive (survivin > 0.9 ng/mL) and showed severe radiographic damage at the start of infliximab treatment compared with survivin-negative (P = 0.027). Patients with high survivin levels were unlikely to respond to infliximab treatment (OR 4.02 [1.22-14.61], P = 0.022) and achieve remission (OR 4.32[1.01-30.11], P = 0.048) compared with patients with low survivin levels. Conclusions: High survivin levels are associated with severe radiographic damage at the start of treatment and a poor response to infliximab. Survivin measurement should be considered an additional tool for aiding the selection and follow-up of antirheumatic treatment. (C) 2012 Elsevier Inc. All rights reserved. Semin Arthritis Rheum 41:652-657 (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
rheumatoid arthritis, infliximab, surviving, treatment
in
Seminars in Arthritis and Rheumatism
volume
41
issue
5
pages
652 - 657
publisher
W.B. Saunders Co.
external identifiers
  • wos:000302928900003
  • scopus:84859434524
ISSN
0049-0172
DOI
10.1016/j.semarthrit.2011.08.005
language
English
LU publication?
yes
id
3f794540-eac9-4154-b963-7dad6c6a8e6d (old id 2571145)
date added to LUP
2012-06-01 08:54:21
date last changed
2017-09-12 13:41:49
@article{3f794540-eac9-4154-b963-7dad6c6a8e6d,
  abstract     = {Objective: To evaluate if the measurement of survivin in the blood of patients with rheumatoid arthritis (RA) undergoing infliximab treatment has predictive value for treatment response. Methods: The study included 87 consecutive RA patients (age 24-89 years, disease duration 18-526 months) treated with regular infusions of influximab. Survivin levels were measured by enzyme-linked immunosorbent assay and evaluated in relation to the total dose of infliximab, disease activity (DAS28), response to infliximab treatment (change in DAS28 > 1.2), and radiographic damage (vdH-Sharp score). Results: Thirty-seven percent of patients were survivin-positive (survivin > 0.9 ng/mL) and showed severe radiographic damage at the start of infliximab treatment compared with survivin-negative (P = 0.027). Patients with high survivin levels were unlikely to respond to infliximab treatment (OR 4.02 [1.22-14.61], P = 0.022) and achieve remission (OR 4.32[1.01-30.11], P = 0.048) compared with patients with low survivin levels. Conclusions: High survivin levels are associated with severe radiographic damage at the start of treatment and a poor response to infliximab. Survivin measurement should be considered an additional tool for aiding the selection and follow-up of antirheumatic treatment. (C) 2012 Elsevier Inc. All rights reserved. Semin Arthritis Rheum 41:652-657},
  author       = {Isgren, Anniella and Forslind, Kristina and Erlandsson, Malin and Axelsson, Carl and Andersson, Sofia and Lund, Anneli and Bokarewa, Maria},
  issn         = {0049-0172},
  keyword      = {rheumatoid arthritis,infliximab,surviving,treatment},
  language     = {eng},
  number       = {5},
  pages        = {652--657},
  publisher    = {W.B. Saunders Co.},
  series       = {Seminars in Arthritis and Rheumatism},
  title        = {High Survivin Levels Predict Poor Clinical Response to Infliximab Treatment in Patients with Rheumatoid Arthritis},
  url          = {http://dx.doi.org/10.1016/j.semarthrit.2011.08.005},
  volume       = {41},
  year         = {2012},
}